Advertisement

Emergency management of community-acquired bacterial pneumonia: what is new since the 2007 Infectious Diseases Society of America/American Thoracic Society guidelines

Published:February 04, 2013DOI:https://doi.org/10.1016/j.ajem.2012.12.002

      Abstract

      Community-acquired pneumonia (CAP) is a major health problem in the United States and is associated with substantial morbidity, mortality, and health care costs. Patients with CAP commonly present to emergency departments where physicians must make critical decisions regarding diagnosis and management of pneumonia in a timely fashion, with emphasis on efficient and cost-effective diagnostic choices, consideration of emerging antimicrobial resistance, timely initiation of antibiotics, and appropriate site-of-care decisions. In light of the burden that pneumonia places on health care systems and the emergency department in particular, this article reviews significant developments in the management of CAP in the United States 5 years since the publication of the 2007 Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of CAP in adults, focusing on recent studies and recommendations for managing CAP, the primary bacterial pathogens responsible for CAP, and trends in resistance, new diagnostic technologies, and newer antimicrobials approved for the treatment of CAP. These new data and additional guidelines pertaining to the treatment of CAP further our knowledge and understanding of this challenging infection. Furthermore, appreciation of the availability of new diagnostic testing and therapeutic options will help meet the demand for improved management of CAP.
      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Schappert S.M.
        • Rechtsteiner E.A.
        Ambulatory medical care utilzation estimates for 2007.
        Vital Health Stat 13. 2011; : 1-38
        • Hall M.J.
        • DeFrances C.J.
        • Williams S.N.
        • et al.
        National Hospital Discharge Survey: 2007 Summary.
        National Health Statistics Reports; no 29. National Center for Health Statistics, Hyattsville, MD2010
        • Marrie T.J.
        • Shariatzadeh M.R.
        Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study.
        Medicine (Baltimore). 2007; 86: 103-111
        • Restrepo M.I.
        • Mortensen E.M.
        • Velez J.A.
        • et al.
        A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU.
        Chest. 2008; 133: 610-617
        • Jencks S.F.
        • Williams M.V.
        • Coleman E.A.
        Rehospitalizations among patients in the Medicare fee-for-service program.
        N Engl J Med. 2009; 360: 1418-1428
        • Jackson M.L.
        • Neuzil K.M.
        • Thompson W.W.
        • et al.
        The burden of community-acquired pneumonia in seniors: results of a population-based study.
        Clin Infect Dis. 2004; 39: 1642-1650
      1. Miniño AM, Murphy SL, Xu J, et al. Deaths: final data for 2008. National vital statistics reports; vol 59 no 10. Hyattsville, MD: National Center for Health Statistics. 2011. http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_10.pdf.

        • Ewig S.
        • Birkner N.
        • Strauss R.
        • et al.
        New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality.
        Thorax. 2009; 64: 1062-1069
        • File Jr., T.M.
        • Marrie T.J.
        Burden of community-acquired pneumonia in North American adults.
        Postgrad Med. 2010; 122: 130-141
      2. Joint Commission. Pneumonia Measures. http://www.jointcommission.org/pneumonia/ Accessed September 7, 2012.

      3. Gesensway D. New thinking on antibiotic timing in CAP patients. Today's Hospitalist. March 2008. www.todayshospitalist.com/index.php?b=articles_read&cnt=526. Accessed August 30, 2012.

        • Fee C.
        • Weber E.J.
        • Bacchetti P.
        • et al.
        Effect of emergency department crowding on pneumonia admission care components.
        Am J Manag Care. 2011; 17: 269-278
        • Moran G.J.
        • Talan D.A.
        • Abrahamian F.M.
        Diagnosis and management of pneumonia in the emergency department.
        Infect Dis Clin North Am. 2008; 22: 53-72
        • Nazarian D.J.
        • Eddy O.L.
        • Lukens T.W.
        • et al.
        Clinical policy: critical issues in the management of adult patients presenting to the emergency department with community-acquired pneumonia.
        Ann Emerg Med. 2009; 54: 704-731
        • Mandell L.A.
        • Wunderink R.G.
        • Anzueto A.
        • et al.
        Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.
        Clin Infect Dis. 2007; 44: S27-S72
      4. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), US Department of Health and Human Services. Guidance for industry, community-acquired bacterial pneumonia: developing drugs for treatment (draft guidance). Rockville, MD: US Dept of Health and Human Services; March 2009.

        • Goto H.
        • Shimada K.
        • Ikemoto H.
        • et al.
        Antimicrobial susceptibility of pathogens isolated from more than 10,000 patients with infectious respiratory diseases: a 25-year longitudinal study.
        J Infect Chemother. 2009; 15: 347-360
        • Wang H.
        • Chen M.
        • Xu Y.
        • et al.
        Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010.
        Int J Antimicrob Agents. 2011; 38: 376-383
        • Zhanel G.G.
        • Palatnick L.
        • Nichol K.A.
        • et al.
        Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.
        Antimicrob Agents Chemother. 2003; 47: 1875-1881
      5. Critchley I, Biek D, Sader H, Jones RN, Krause K. Evaluation of pneumococci from the United States (USA) pediatric patients isolated during the 2009 AWARE program (abstract G3-180). 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011 September 17-20; Chicago, IL.

        • Hidron A.I.
        • Low C.E.
        • Honig E.G.
        • et al.
        Emergence of community-acquired methicillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia.
        Lancet. 2009; 9: 384-392
        • Spellberg B.
        • Blaser M.
        • et al.
        • Infectious Diseases Society of America (IDSA)
        Combating antimicrobial resistance: policy recommendations to save lives.
        Clin Infect Dis. 2011; 52: S397-S428
        • Richter S.S.
        • Heilmann K.P.
        • Dohrn C.L.
        • et al.
        Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005.
        Clin Infect Dis. 2009; 48: e23-e33
        • File Jr., T.M.
        Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia.
        Clin Microbiol Infect. 2006; 12: 31-41
      6. Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2007. http://www.cdc.gov/ncidod/abcs/reports-findings/survreports/spneu07.pdf. Accessed April 6, 2012.

      7. Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis [serial on the Internet]. 2009 August. http://wwwns.cdc.goc/eid/article/15/8/08-1187.htm. Accessed April 6, 2012.

        • Patel S.N.
        • McGeer A.
        • Melano R.
        • et al.
        • for the Canadian Bacterial Surveillance Network
        Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.
        Antimicrob Agents Chemother. 2011; 55: 3703-3708
        • Centers for Disease Control, Prevention
        Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease, United States, 1998-2003.
        MMWR Morb Mortal Wkly Rep. 2005; 54: 893-897
        • Lexau C.A.
        • Lynfield R.
        • Danila R.
        • et al.
        Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine.
        JAMA. 2005; 294: 2043-2051
        • Whitney C.G.
        • Farley M.M.
        • Hadler J.
        • et al.
        Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.
        N Engl J Med. 2003; 348: 1737-1746
        • Messina A.F.
        • Katz-Gaynor K.
        • Barton T.
        • et al.
        Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005.
        Pediatr Infect Dis J. 2007; 26: 461-467
        • Pelton S.I.
        • Huot H.
        • Finkelstein J.A.
        • et al.
        Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine.
        Pediatr Infect Dis J. 2007; 26: 468-472
        • Gertz Jr., R.E.
        • Li Z.
        • Pimenta F.C.
        • et al.
        Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era.
        J Infect Dis. 2010; 201: 770-775
        • Farrell D.J.
        • Klugman K.P.
        • Pichichero M.
        Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States.
        Pediatr Infect Dis J. 2007; 26: 123-128
        • Moore M.R.
        • Gertz Jr., R.E.
        • Woodbury R.L.
        • et al.
        Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005.
        J Infect Dis. 2008; 197: 1016-1027
        • Hindler J.F.
        • Stelling J.
        Analysis and presentation of cumulative antibiograms: a new consensus guideline from the Clinical and Laboratory Standards Institute.
        Clin Infect Dis. 2007; 44: 867-873
        • Pakyz A.L.
        The utility of hospital antibiograms as tools for guiding empiric therapy and tracking resistance. Insights from the Society of Infectious Diseases Pharmacists.
        Pharmacotherapy. 2007; 27: 1306-1312
      8. Jacobs MR, Bajaksouzian S, Good CE, Windau AR, Gonzalez B. Evolution of Streptococcus pneumoniae serotypes following introduction of the 13-valent conjugate pneumococcal vaccine [poster G3-773]. Presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2011; Chicago, IL.

        • Kaplan S.L.
        • Barson W.J.
        • Lin P.L.
        • et al.
        Serotype 19A is the most common serotype causing invasive pneumococcal infections in children.
        Pediatrics. 2010; 125: 429-436
        • Mandell L.A.
        • Wunderink R.
        Methicillin-resistant Staphylococcus aureus and community-acquired pneumonia: an evolving relationship.
        Clin Infect Dis. 2012; 54: 1134-1136
        • Attridge R.T.
        • Frei C.R.
        Increasing incidence of Staphylococcus aureus pneumonia among patients admitted to United States hospitals from community settings.
        in: Poster presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, CA2009
        • Carillo-Marquez M.A.
        • Hulten K.G.
        • Hammerman W.
        • et al.
        Staphylococcus aureus pneumonia in children in the era of community-acquired methicillin-resistance at Texas Children's Hospital.
        Pediatr Infect Dis. 2011; 30: 545-550
        • Erdem G.
        • Bergert L.
        • Len K.
        • et al.
        Radiological findings of community-acquired methicillin-resistant and methicillin-susceptible Staphylococcus aureus pediatric pneumonia in Hawaii.
        Pediatr Radiol. 2010; 40: 1768-1773
        • File Jr., T.M.
        • Low D.E.
        • Ekburg P.B.
        • et al.
        Integrated analysis of FOCUS 1 and FOCUS 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.
        Clin Infect Dis. 2010; 51: 1395-1405
        • Moran G.J.
        • Krishnadasan A.
        • Gorwitz R.J.
        • et al.
        Prevalence of methicillin-resistant Staphylococcus aureus as an etiology of community-acquired pneumonia.
        Clin Infect Dis. 2012; 54: 1126-1133
        • Rybak M.
        • Lomaestro B.
        • Rotschafer J.C.
        • et al.
        Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.
        Am J Health Syst Pharm. 2009; 66: 82-98
        • Rubinstein E.
        • Kollef M.H.
        • Nathwani D.
        Pneumonia caused by methicillin-resistant Staphylococcus aureus.
        Clin Infect Dis. 2008; 46: S378-S385
        • Klevens R.M.
        • Morrison M.A.
        • Nadle J.
        • et al.
        Invasive methicillin-resistant Staphylococcus aureus infections in the United States.
        JAMA. 2007; 298: 1763-1771
        • Moran G.J.
        • Krishnadasan A.
        • Gorwitz R.J.
        • et al.
        Methicillin-resistant S. aureus infections among patients in the emergency department.
        N Engl J Med. 2006; 355: 666-674
        • Moran G.J.
        • Amii R.N.
        • Abrahamian F.M.
        • et al.
        Methicillin-resistant Staphylococcus aureus in community-acquired skin infections.
        Emerg Infect Dis. 2005; 11: 928-930
        • Pallin D.J.
        • Egan D.J.
        • Pelletier A.J.
        • et al.
        Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus.
        Ann Emerg Med. 2008; 51: 291-298
        • Talan D.A.
        • Krishnadasan A.
        • Gorwitz R.J.
        • et al.
        Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008.
        Clin Infect Dis. 2011; 53: 144-149
        • Tillotson G.S.
        • Draghi D.C.
        • Sahm D.F.
        • et al.
        Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study.
        J Antimicrob Chemother. 2008; 62: 109-115
        • David M.
        • Daum R.
        Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic.
        Clin Microbiol Rev. 2010; 23: 616-687
        • Francis J.S.
        • Doherty M.C.
        • Lopatin U.
        • et al.
        Severe community-onset pneumonia in healthy adults caused by methicillin-resitant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes.
        Clin Infect Dis. 2005; 40: 100-107
        • Hageman J.C.
        • Uyeki T.M.
        • Francis J.S.
        • et al.
        Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season.
        Emerg Infect Dis. 2006; 12: 894-899
        • Kallen A.J.
        • Brunkard J.
        • Moore Z.
        • et al.
        Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season.
        Ann Emerg Med. 2009; 53: 358-365
        • Kallen A.J.
        • Reed C.
        • Patton M.
        • et al.
        Staphylococcus aureus community-onset pneumonia in patients admitted to children's hospitals during autumn and winter of 2006-07.
        Epidemiol Infect. 2010; 138: 666-672
        • Liu C.
        • Bayer A.
        • Cosgrove S.E.
        • et al.
        Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
        Clin Infect Dis. 2011; 52: e18-e55
        • Rybak M.J.
        • Lomaestro B.M.
        • Rotschafer J.C.
        • et al.
        Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists.
        Clin Infect Dis. 2009; 49: 325-327
        • Niederman M.S.
        • McCombs J.S.
        • Unger A.N.
        • et al.
        The cost of treating community-acquired pneumonia.
        Clin Ther. 1998; 20: 820-837
        • Dean N.C.
        • Jones J.P.
        • Aronsky D.
        • et al.
        Hospital admission decision for patients with community-acquired pneumonia: variability among physicians in an emergency department.
        Ann Emerg Med. 2012; 59: 35-41
        • Fine M.J.
        • Auble T.E.
        • Yealy D.M.
        • et al.
        A prediction rule to identify low-risk patients with community-acquired pneumonia.
        N Engl J Med. 1997; 336: 243-250
        • Lim W.S.
        • van der Eerden M.M.
        • Laing R.
        • et al.
        Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study.
        Thorax. 2003; 58: 377-382
        • Chalmers J.D.
        • Singanayagam A.
        • Akram A.R.
        • et al.
        Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis.
        Thorax. 2010; 65: 878-883
        • Loke Y.K.
        • Kwok C.S.
        • Niruban A.
        • et al.
        Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis.
        Thorax. 2010; 65: 884-890
        • Charles P.G.
        • Wolfe R.
        • Whitby M.
        • et al.
        SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia.
        Clin Infect Dis. 2008; 47: 375-384
        • Kelly A.M.
        • McAlpine R.
        • Kyle E.
        Venous pH can safely replace arterial pH in the initial evaluation of patients in the emergency department.
        Emerg Med J. 2001; 18: 340-342
        • Brown S.M.
        • Jones B.E.
        • Jephson A.R.
        • et al.
        Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia.
        Crit Care Med. 2009; 37: 3010-3016
        • Liapikou A.
        • Ferrer M.
        • Polverino E.
        • et al.
        Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission.
        Clin Infect Dis. 2009; 48: 377-385
        • Chalmers J.D.
        • Taylor J.K.
        • Mandal P.
        • et al.
        Validation of the Infectious Diseases Society of America/American Thoracic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care.
        Clin Infect Dis. 2011; 53: 503-511
        • Moran G.
        • Talan D.
        Pneumonia, Chapter 75: In: Rosen's emergency medicine: concepts and clinical practice. 7th ed. Mosby/Elsevier, Philadelphia, PA2010
        • Nassisi D.
        • Oishi M.L.
        Evidence-based guidelines for evaluation and antimicrobial therapy for common emergency department infections.
        Emerg Med Pract. 2012; 14: 1-28
        • Syrjälä H.
        • Broas M.
        • Suramo I.
        • Ojala A.
        • Lähde S.
        High-resolution computed tomography for the diagnosis of community-acquired pneumonia.
        Clin Infect Dis. 1998; 27: 358-363
        • Cortellaro F.
        • Colombo S.
        • Coen D.
        • et al.
        Lung ultrasound is an accurate diagnostic tool for the diagnosis of pneumonia in the emergency department.
        Emerg Med J. 2012; 29: 19-23
        • Parlamento S.
        • Copetti R.
        • Di Bartolomeo S.
        Evaluation of lung ultrasound for the diagnosis of pneumonia in the ED.
        Am J Emerg Med. 2009; 27: 379-384
        • Napoli A.M.
        • Fischer C.M.
        • Pines J.M.
        • et al.
        Absolute lymphocyte count in the emergency department predicts a low CD4 count in admitted HIV-positive patients.
        Acad Emerg Med. 2011; 18: 385-389
        • Bartlett J.
        Diagnostic tests for agents of community-acquired pneumonia.
        Clin Infect Dis. 2011; 52: S296-S304
        • van der Eerden M.M.
        • Vlaspolder F.
        • de Graaff C.S.
        • et al.
        Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study.
        Thorax. 2005; 60: 672-678
        • Weatherall C.
        • Paoloni R.
        • Gottlieb T.
        Point-of-care urinary pneumococcal antigen test in the emergency department for community acquired pneumonia.
        Emerg Med J. 2008; 25: 144-148
        • Sopena N.
        • Sabrià M.
        Multicenter study of hospital-acquired pneumonia in non-ICU patients.
        Chest. 2005; 127: 213-219
        • Ginocchio C.C.
        Strengths and weaknesses of FDA-approved/cleared diagnostic devices for the molecular detection of respiratory pathogens.
        Clin Infect Dis. 2011; 52: S312-S325
        • Babin S.M.
        • Hsieh Y.H.
        • Rothman R.E.
        • Gaydos C.A.
        A meta-analysis of point-of-care laboratory tests in the diagnosis of novel 2009 swine-lineage pandemic influenza A (H1N1).
        Diagn Microbiol Infect Dis. 2011; 69: 410-418
        • Faix D.J.
        • Sherman S.S.
        • Waterman S.H.
        Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans.
        N Engl J Med. 2009; 361: 728-729
        • Lieberman D.
        • Shimoni A.
        • Shemer-Avni Y.
        • et al.
        Respiratory viruses in adults with community-acquired pneumonia.
        Chest. 2010; 138: 811-816
        • Peterson L.R.
        Molecular laboratory tests for the diagnosis of respiratory tract infection due to Staphylococcus aureus.
        Clin Infect Dis. 2011; 52: S361-S366
      9. US Food and Drug Administration. FDA expands use for FilmArray Respiratory Panel. Press release. May 15, 2012. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm304177.htm. Accessed June 12, 2012.

        • Ecker D.J.
        • Sampath R.
        • Massire C.
        • et al.
        Ibis T5000: a universal biosensor approach for microbiology.
        Nat Rev Microbiol. 2008; 6: 553-558
        • Ecker D.J.
        • Sampath R.
        • Blyn L.B.
        • et al.
        Rapid identification and strain-typing of respiratory pathogens for epidemic surveillance.
        Proc Natl Acad Sci USA. 2005; 102: 8012-8017
        • Endimiani A.
        • Hujer K.M.
        • Hujer A.M.
        • et al.
        Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia?.
        Clin Infect Dis. 2011; 52: S373-S383
        • Oosterheert J.J.
        • van Loon A.M.
        • Schuurman R.
        • et al.
        Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection.
        Clin Infect Dis. 2005; 41: 1438-1444
        • Schuetz P.
        • Christ-Crain M.
        • Thomann R.
        • et al.
        Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial.
        JAMA. 2009; 302: 1059-1066
        • Long W.
        • Deng X.
        • Zhang Y.
        • et al.
        Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia.
        Respirology. 2011; 16: 819-824
        • Huang D.T.
        • Weissfeld L.A.
        • Kellum J.A.
        • et al.
        Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia.
        Ann Emerg Med. 2008; 52: 48-58
        • Shorr A.F.
        • Zilberberg M.D.
        • Reichley R.
        • et al.
        Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department.
        Clin Infect Dis. 2012; 54: 193-198
      10. TYGACIL prescribing information. Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; 2011.

        • Tanaseanu C.
        • Bergallo C.
        • Teglia O.
        • et al.
        Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
        Diagn Microbiol Infect Dis. 2008; 61: 329-338
        • Cai Y.
        • Wang R.
        • Liang B.
        • et al.
        Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.
        Antimicrob Agents Chemother. 2011; 55: 1162-1172
      11. TEFLARO [prescribing information]. New York, NY: Forest Laboratories, Inc.; 2012.

      12. Joint Commission. Specifications Manual for National Hospital Quality Measures. http://www.jointcommission.org/specifications_manual_for_national_hospital_inpatient_quality_measures/. Accessed November 15, 2011.

        • File Jr., T.M.
        • Low D.E.
        • Eckburg P.B.
        • et al.
        FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
        J Antimicrob Chemother. 2011; 66: iii19-iii32
        • Low D.E.
        • File Jr., T.M.
        • Eckburg P.B.
        • et al.
        FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
        J Antimicrob Chemother. 2011; 66: iii33-iii44
        • Eckburg P.B.
        • Friedland H.D.
        • Llorens L.
        • et al.
        Day 4 clinical response of ceftaroline fosamil versus ceftriaxone for community-acquired bacterial pneumonia.
        Infect Dis Clin Pract. 2012; 20: 254-260
        • Rank D.R.
        • Friedland H.D.
        • Laudano J.B.
        Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.
        J Antimicrob Chemother. 2011; 66: iii53-iii59
        • Corey G.R.
        • Wilcox M.
        • Talbot G.H.
        • et al.
        Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.
        Clin Infect Dis. 2010; 51: 641-650
        • Tenover F.C.
        • Moellering Jr., R.C.
        The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.
        Clin Infect Dis. 2007; 44: 1208-1215
        • Steinkraus G.
        • White R.
        • Friedrich L.
        Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-2005.
        J Antimicrob Chemother. 2007; 60: 788-794
        • Appelbaum P.C.
        Microbiology of antibiotic resistance in Staphylococcus aureus.
        Clin Infect Dis. 2007; 45: S165-S170
        • van Hal S.J.
        • Lodise T.P.
        • Paterson D.L.
        The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.
        Clin Infect Dis. 2012; 54: 755-771
        • Jones R.N.
        • Stilwell M.G.
        • Hogan P.A.
        • et al.
        Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program.
        Antimicrob Agents Chemother. 2007; 51: 1491-1493
        • Mutnick A.H.
        • Biedenbach D.J.
        • Turnidge D.
        • et al.
        Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000.
        Diagn Microbiol Infect Dis. 2002; 43: 65-73
      13. Zyvox prescribing information. New York, NY: Pfizer, Inc., 2012.

        • Farrell D.J.
        • Mendes R.E.
        • Ross J.E.
        • et al.
        LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States.
        Antimicrob Agents Chemother. 2011; 55: 3684-3690
        • Sánchez García M.
        • la Torre MA De
        • Morales G.
        • et al.
        Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit.
        JAMA. 2010; 303 (2260-2264)
        • Rubinstein E.
        • Isturiz R.
        • Standiford H.C.
        • et al.
        Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies.
        Antimicrob Agents Chemother. 2003; 47: 1824-1831
        • Vinh D.C.
        • Rubinstein E.
        Linezolid: a review of safety and tolerability.
        J Infect. 2009; 59: S59-S74
      14. Food and Drug Administration. FDA Drug Safety Communication: updated information about the drug interaction between linezolid (Zyvox) and serotonergic psychiatric medications. http://www.fda.gov/Drugs/DrugSafety/ucm276251.htm. October 2011. Accessed November 15, 2011.